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MicroRNAs (miRNAs) are a class of small noncoding RNAs involved in posttranscriptional regulation.
miRNAs are utilized in organisms ranging from plants to higher mammals, and data have shown that DNA
viruses also use this method for host and viral gene regulation. Here, we report the sequencing of the small
RNAs in rat cytomegalovirus (RCMV)-infected fibroblasts and persistently infected salivary glands. We
identified 24 unique miRNAs that mapped to hairpin structures found within the viral genome. While most
miRNAs were detected in both samples, four were detected exclusively in the infected fibroblasts and two were
specific for the infected salivary glands. The RCMV miRNAs are distributed across the viral genome on both
the positive and negative strands, with clusters of miRNAs at a number of locations, including near viral genes
r1 and r111. The RCMV miRNAs have a genomic positional orientation similar to that of the miRNAs
described for mouse cytomegalovirus, but they do not share any substantial sequence conservation. Similar to
other reported miRNAs, the RCMV miRNAs had considerable variation at their 3 and 5 ends. Interestingly,
we found a number of specific examples of differential isoform usage between the fibroblast and salivary gland
samples. We determined by real-time PCR that expression of the RCMV miRNA miR-r111.1-2 is highly
expressed in the salivary glands and that miR-R87-1 is expressed in most tissues during the acute infection
phase. Our study identified the miRNAs expressed by RCMV in vitro and in vivo and demonstrated that
expression is tissue specific and associated with a stage of viral infection.
MicroRNAs (miRNAs) are small noncoding RNAs involved
in posttranscriptional regulation through binding to comple-
mentary sequences in target mRNAs resulting in gene silenc-
ing (4). miRNAs are ubiquitous among multicellular eukary-
otic organisms, including plants and higher mammals, and have
diverse roles in many different biological processes, including
development, differentiation, proliferation, apoptosis, and he-
matopoiesis (35, 51). In addition to eukaryotic miRNAs, DNA
viruses, mainly of the Herpesvirus family, have been shown to
encode miRNAs. Bioinformatic, sequencing, and direct clon-
ing approaches have led to the identification of more than 140
viral miRNAs (reviewed in reference 55). The role of viral
miRNAs is proposed to include the targeting of cellular genes
to induce a favorable replication environment or to evade the
host immune system and the targeting of their own viral ge-
nome to regulate viral gene expression during persistence or
latency/reactivation (22, 55).
Human cytomegalovirus (HCMV) is known to encode at
least 14 miRNAs. HCMV is a ubiquitous betaherpesvirus, and
primary infection results in lifelong persistent/latent infection
of the host. Infection of immunocompetent hosts is generally
asymptomatic, but infection of immunocompromised hosts can
lead to high morbidity and mortality. HCMV has been linked
to the development of atherosclerosis, arterial restenosis fol-
lowing angioplasty, and solid-organ transplant vascular sclero-
sis (TVS) (40, 41, 57). HCMV infection nearly doubles the
5-year rate of cardiac graft failure due to accelerated TVS (20)
and doubles the rate of liver graft loss at 3 years (14, 52). Since
the betaherpesviruses, including HCMV, are highly species
specific, effective animal models have been established to in-
vestigate the role of CMV infection in chronic disease. We
have utilized a rat cytomegalovirus (RCMV) infection system
to model a number of human diseases associated with HCMV
infections, including solid-organ transplant rejection and reste-
nosis following angioplasty (26, 27, 29–31, 36–39, 45, 46, 56, 58,
62–64). Similar to human infection, infection of immunocom-
petent rats leads to a limited subclinical infection that persists
lifelong in host bone marrow and columnar epithelial cells of
the salivary glands (28). RCMV infection of immunocompro-
mised rats (i.e., rats undergoing immunosuppressive treatment
for the prevention of allograft rejection) leads to infection of
most host tissues and organs. We have shown that RCMV gene
expression is highly restricted in tissues from allograft recipi-
ents following infection. In fact, the highly expressed genes in
tissues from the infected rats are hypothesized to be involved
in host cell manipulation and/or immune evasion, which allows
the virus to persist by turning over small amounts of infectious
virus while remaining undetected by the immune system (65).
However, the mechanisms by which CMV controls viral gene
expression in vivo are still unknown. Recent studies suggest
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that miRNAs may play an important role in regulating CMV
gene expression and latency (23). The aim of the present study
was to identify the miRNAs encoded in the RCMV genome
and determine expression levels in tissue culture-infected fi-
broblasts, as well as in persistently infected tissues from
RCMV-infected heart allograft recipients. Our elucidation of
the RCMV miRNAs expressed during lytic and persistent in
vivo infections is crucial for our understanding of their role in
CMV persistence, pathogenesis, and disease.
MATERIALS AND METHODS
RCMV. The titers of salivary gland-derived stocks of the Maastricht strain of
RCMV were determined using primary rat lung fibroblasts (RFL6 cells) (5, 6).
Plaque assays were performed in confluent 24-well plates by infection with an
appropriate serial virus dilution in 0.2 ml of medium and then incubation at 37°C
for 90 min. Following incubation, the infected cells were rinsed with phosphate-
buffered saline (PBS) and overlaid with 1 ml Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal calf serum (FCS), nonessential
amino acids, penicillin-streptomycin, and 20 mM L-glutamine with a final con-
centration of 0.6% agarose. After 7 days, the cells were fixed in 3.7% formalde-
hyde in PBS and stained with 0.05% aqueous methylene blue. The plaques were
counted by light microscopy.
RCMV infection of tissue culture cells. RFL6 cells were maintained in DMEM
supplemented with 10% FCS and penicillin-streptomycin-glutamine (42, 62). For
the cloning and sequencing of the RCMV miRNAs from in vitro-infected cells,
RFL6 cells were plated onto 150-mm dishes (Costar). These cells were infected
with RCMV upon confluence at a multiplicity of infection (MOI) of 0.1. After
3 h, the cells were washed three times with PBS. The infected cells were har-
vested at 72 h postinfection (hpi) by one washing with PBS and then addition of
3 ml of Trizol reagent. The reagent was allowed to lyse the cells for 5 min at room
temperature. Subsequently, the samples were stored frozen at 80°C. For
miRNA real-time PCR analysis of the RCMV miRNAs miR-R87-1 and miR-
r111.2-6 in infected tissue culture cells, RFLs were plated into six-well plates.
The cells were infected with RCMV (MOI of 0.1) and harvested by addition of
Trizol, as described above, at 6, 24, and 48 hpi.
Preparation of rat tissues from heart allograft recipients. To identify the
RCMV miRNAs expressed in vivo, we sequenced the small RNAs from total
RNA samples isolated from salivary glands from rat allograft recipients at 21
days postinfection (dpi) (62, 65). Rat heart transplant surgeries were performed
as previously described (45, 62–65). Various tissues (native and graft heart,
salivary gland, spleen, liver, kidney, and lung) were collected from infected heart
allograft recipients at 7 and 28 dpi (61, 62, 65) for real-time PCR analysis of the
RCMV miRNAs miR-R87-1 and miR-r111.1-2. For each analysis, total RNA
was prepared from approximately 0.25 g of rat tissue using the Trizol method. All
animals were housed in the Portland VA Medical Center animal facilities in a
specific-pathogen-free room. This facility is AAALAC accredited and complies
with the requirements for animal care stipulated by the USDA and HHS.
miRNA deep sequencing. Deep sequencing was performed by LC Sciences
(Houston, TX). Accordingly, for each sample, about 10 g of total RNA was size
fractionated on a 15% Tris-borate-EDTA (TBE) urea polyacrylamide gel and a
15- to 50-bp fraction was excised. The small RNA fraction was eluted from the
gel slice in 500 l of 0.3 M NaCl and precipitated by the addition of ethanol.
According to the Illumina Solexa instructions, both 5 and 3RNA adaptors were
added using T4 RNA ligase and the ligated RNA was again size fractionated on
a 15% TBE polyacrylamide gel. The fraction containing the 65- to 100-bp region
was excised from the gel and precipitated. The recovered RNA was converted to
single-stranded cDNA using Moloney murine leukemia virus reverse transcrip-
tase (RT) and the Illumina Solexa RT primer. The cDNA was amplified with Pfx
DNA polymerase for 20 cycles by PCR using the Illumina Solexa small RNA
primer set. PCR products were purified on a 12% polyacrylamide gel, and the 80-
to 120-bp fraction was excised from the gel and eluted and precipitated as
described above. The samples were resuspended and sequenced using the Illu-
mina Solexa G1 sequencer. Raw sequencing data were filtered for composition,
the presence of adaptor dimers, length, sequence repetition, and copy number.
The filtered data were then mapped to current miR databases, the Rattus nor-
vegicus genome, and the RCMV genome (AF232689).
Northern blot analysis. Total RNA was isolated from infected (72 hpi) or
uninfected rat fibroblasts using the Trizol (Invitrogen) method. To determine the
kinetics of RCMV miRNA gene expression, another set of fibroblasts were
harvested at 0, 8, 48, and 48 hpi in the presence of foscarnet (1:250 125 mM).
Equal volumes of formamide and loading dye were added to each 20-g sample
of RNA. The samples were boiled for 5 min and cooled on ice prior to loading
onto a 15% urea-acrylamide gel. The gel was transferred to GeneScreen plus
(Perkin-Elmer) membrane in 1 TBE. Probes were produced by end labeling
oligonucleotides using polynucleotide kinase (Fermentas) with [-32P]dATP.
The total labeled probe was hybridized to the blot overnight at 38°C in
PerfectHyb Plus (Sigma Aldrich). The blot was washed two times with a low-
stringency buffer (2 SSC [1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate],
0.05% sodium dodecyl sulfate [SDS]) and one time with a high-stringency buffer
(0.1 SSC, 0.1% SDS) at 38°C. The blot was exposed to autoradiographic film
(Kodak BioMax MS) overnight at 80 C.
Quantitative RT-PCR detection of RCMV miRNAs. Real-time RT-PCR was
used to quantify the RCMV miRNA expression in RCMV-infected fibroblasts
and tissues from RCMV-infected heart allograft recipients. miRNA cDNA was
generated from total RNA using the TaqMan microRNA reverse transcription
kit (Applied Biosystems) in 15-l reaction mixtures containing 1.5 pmol of the
miRNA-specific RT primer and 100 ng of total RNA. The sequences of the
miR-R87.1 and miR-r111.1-2 RT primers are GTC GTC TCC AGT GCA GGG
TCC GAG GTA TTC GCA CTG GAT ACG ACG AGTT G and GTC GTC
TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CGC
CG, respectively. Samples were incubated in an Applied Biosystems 9700 ther-
mocycler at 16°C for 30 min, 42°C for 30 min, and then 85°C for 5 min. Real-time
PCR (TaqMan) was used to quantify miRNA levels from 1.5 l of the cDNA
reaction mixture run in a ABI StepOnePlus real-time PCR machine using 40
cycles of 95°C for 15 s and 60°C for 1 min (63–65). The primer and probe sets
used included miR-R87-1 forward primer GCT CGA AGA ACG GGT GC,
reverse primer GTG CAG GGT CCG AGG T, and probe TGG ATA CGA
CGA GTT G and miR-r111.1-2 forward primer GCT CGA AAC AAC GTG
GA, reverse primer GTG CAG GGT CCG AGG T, and probe TGG ATA CGA
CAC GCC G. Oligonucleotides with the miRNA sequences for miR-R87-1 and
miR-r111.1-2 were used as quantification standards. Data are presented as rel-
ative copy numbers per 10 ng of total input RNA.
TABLE 1. Distribution of small RNAs in RCMV-infected fibroblasts and salivary glands
Cells Sequence no. Sequence % Family no. Family %
RCMV-infected fibroblasts
Raw 6,665,287 100.00 414,447 100.00
Mappable 3,731,474 55.98 27,168 6.56
Mapped (total) 2,754,863 41.33 13,288 3.21
Unmapped (total) 976,611 14.65 13,880 3.35
Mapped to RCMV genome 305,522 4.60 1,611 0.39
RCMV-infected salivary glands
Raw 7,230,718 100.00 377,359 100.00
Mappable 2,909,115 40.23 20,029 5.31
Mapped (total) 2,369,736 32.77 11,139 2.95
Unmapped (total) 539,379 7.46 8,890 2.36
Mapped to RCMV genome 4,159 0.06 145 0.03
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RESULTS
Identification of RCMV miRNAs. To identify the miRNAs
encoded by RCMV, we deep sequenced the small RNAs ex-
pressed in RCMV-infected fibroblasts and in persistently in-
fected salivary glands from a rat infected for 21 days. We have
previously demonstrated that salivary glands from rats infected
for 21 days have highly restricted viral gene expression profiles,
limited to a small number of genes involved in immune evasion
and persistence (65). For sequencing experiments, total RNA
was extracted and the small RNAs (15 to 25 bp) were isolated
by polyacrylamide gel electrophoresis. The RNAs were ligated
to 5 and 3 primers and deep sequenced using an Illumina
Solexa G1 sequencer. The total reads were filtered for com-
position, length, and junk.
A total of 6,665,287 reads were made in the RCMV-infected
fibroblast sample, and nearly 41% of the sequences were
mapped to either the cellular miR database or the rat genome
(Table 1). A total of 7,230,718 reads were made in the RCMV-
infected salivary gland sample, and nearly 33% of the se-
quences were mapped to the miR database and/or to the rat
genome. Approximately 87% of the sequenced small RNAs
from the infected fibroblast sample and 85% from the infected
salivary glands were between 19 and 23 bp. A list of the cellular
miRNAs detected in the infected fibroblasts and salivary
TABLE 2. RCMV miRs detected in infected fibroblasts and salivary glands
RCMV-miR name miR sequenceb miR length(nt)
Copy no. of
isoform
Copy no. of
all isoforms Strand
Genomic positiona
miR
start
miR
end
Sequenced from RCMV-infected
fibroblasts (72 hpi)
miR-r6-1 TCGACCTCAAGCCGTTCGGGAC 22 131 996  8671 8692
miR-OriLyt-1 GACGGGGTCTCGGGCTCCTGA 21 178 583  77402 77422
miR-OriLyt-2 TGGCTCGCGTCGCCATGGAGAC 22 30 97  78953 78974
miR-R87-1 TCGAAGAACGGGTGCAACTC 20 68,629 166,117  113930 113949
miR-R91-1 GGACTCGGAGTCGTCGGACGCT 22 1,706 6,491  121165 121186
miR-r111.1-1 CGCACCGGCGTCGAGCACGTAC 22 753 2,857  152214 152235
miR-r111.1-2 TCGAAACAACGTGGAACGGCGT 22 11,212 30,084  152728 152749
miR-r111.1-3 TCGGGGGCGGTCGGAAGGTCC 21 78 427  152891 152911
miR-r1-1 GTAAGATGGAATCACCGGAGG 21 5,265 26,402  1024 1044
miR-r1-2 TTTCTCTCGTGCTCCGTGTCGC 22 610 1,030  1187 1208
miR-r1-3 TGATGCGGGGTAGGGGAGTGAG 22 183 473  1154 1175
miR-r1-4 CCAGGTGGAGGAGTCCGGTC 20 85 156  1281 1300
miR-r37-1 TTGTCGTGGGTTTCGT 16 72 77  34740 34755
miR-r43.1-1 TTATCAGCCGGCAAGCACCCAGG 23 1,261 5,577  40748 40770
miR-r43.1-2 AGGGGTTCGCCGGCCGATATCG 22 40 58  40795 40816
miR-R90-1 GACCGGGGATCGTCGAACGAC 21 66 192  121129 121149
miR-r111.2-1 TACGTGCTCGACGCCGGTGCGG 22 13 47  152213 152234
miR-r111.2-2 CTTCGAGTGCGTGTCCGATAGC 22 101 347  152238 152259
miR-r111.2-3 AATCGGACACCCGCTCGCGAAGG 23 164 1,072  152292 152314
miR-r111.2-4 CCCGAAACTCCGTCGAACGCG 21 418 1,075  152762 152782
miR-r111.2-5 TTCCACGTTGTTTCGAGGCCT 21 1,637 3,770  152723 152743
miR-r111.2-6 TTCGCGGACGATCGAGGAG 19 14,331 57,461  152854 152872
Sequenced from salivary glands
(21 dpi)
miR-r6-1 TCGACCTCAAGCCGTTCGGGAC 22 9 74  8671 8692
miR-OriLyt-1 GACGGGGTCTCGGGCTCCTGA 21 22 42  77402 77422
miR-OriLyt-2 TGGCTCGCGTCGCCATGGAGACA 23 5 8  78953 78975
miR-R87-1 TCGAAGAACGGGTGCAACTC 20 402 926  113930 113949
miR-R91-1 GGACTCGGAGTCGTCGGACGCT 22 12 54  121165 121186
miR-r111.1-1 CGCACCGGCGTCGAGCACGTAC 22 28 113  152214 152235
miR-r111.1-2 TCGAAACAACGTGGAACGGCGT 22 646 1,942  152728 152749
miR-r111.1-3 TCGGGGGCGGTCGGAAGGT 19 7 19  152891 152909
miR-r170-1 ACCGACTGAGCGGACGG 17 6 6  224343 224359
miR-r1-1 GTAAGATGGAATCACCGGAGGC 22 51 198  1023 1044
miR-r1-2 TTTCTCTCGTGCTCCGTGTCGC 22 6 6  1187 1208
miR-r1-3 TGATGCGGGGTAGGGGAGTGAGA 23 3 3  1153 1175
miR-r37-1 TTGTCGTGGGTTTCGT 16 143 147  34740 34755
miR-r43.1-1 TTATCAGCCGGCAAGCACCCA 21 15 36  40750 40770
miR-r95.1-1 GACGGAGAGCGAACGGT 17 4 4  128079 128095
miR-r111.2-2 CTTCGAGTGCGTGTCCGATAG 21 10 20  152239 152259
miR-r111.2-3 ATCGGACACCCGCTCGCGAAGGA 23 12 31  152291 152313
miR-r111.2-4 CCCGAAACTCCGTCGAACGCG 21 17 30  152762 152782
miR-r111.2-5 TTCCACGTTGTTTCGAGGCCT 21 45 101  152723 152743
miR-r111.2-6 TTCGCGGACGATCGAGGAGGCC 22 87 399  152851 152872
a Positions are given relative to the published genomic sequence of the Maastricht strain of RCMV.
b Shown is the predominant isoform sequence.
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glands is available at http://www.ohsu.edu/vgti/suppdata.htm.
Of the 976,611 unmapped sequences from the RCMV-infected
fibroblasts 305,522 (31%) mapped to hairpin structures within
the RCMV genome. However, the number of sequences map-
ping to the RCMV genome from the infected salivary gland
sample was only 0.7% of the total reads (4,159 total counts).
The remainder of the unmapped sequences most likely repre-
sent RNA degradation products, noncoding RNAs, or as-yet-
unrealized cellular miRNAs.
We identified 24 unique miRNAs in the RCMV-infected
samples (fibroblasts and salivary gland tissue combined) that
mapped to hairpin structures found within the viral genome
(Table 2; http://www.ohsu.edu/vgti/suppdata.htm). Of the 24
RCMV miRNAs, 22 were expressed in the fibroblast sample,
with 4 (miR-r1-4, miR-r43.1-2, miR-R90-1, and miR-r111.2-1)
being uniquely detected in this sample and not in salivary gland
tissue. Twenty viral miRNAs were detected in the salivary
glands; 18 of these were also detected in the fibroblasts, and
two RCMV-encoded miRNAs (miR-r95.1-1 and miR-r170-1)
were only present in the salivary gland tissues. The viral
miRNAs ranged from 16 to 23 nucleotides (nt) in length;
however, most were between 19 and 22 nt. As expected, the
overall viral miRNA copy number in the salivary glands was
lower than in the infected fibroblasts, which is most likely due
to the lower infection rate found in vivo. Expression profiles
(types of miRNAs and relative levels) of the RCMV miRNAs
are, for the most part, consistent under both in vitro and in vivo
conditions. Accordingly, the most highly expressed of the viral
miRNAs, miR-R87-1, miR-r111.1-2, miR-r111.2-5, and miR-
r1-1, are commonly expressed under both conditions (Table 2).
A small number of RCMV miRNAs are expressed at low
levels, and it is possible that their discovery alone might be due
to the high sensitivity of the deep sequencing methods em-
ployed for this study. To validate the expression of the RCMV
miRNAs, we performed Northern blot analysis of RNA ex-
tracted from RCMV-infected RFL6 fibroblasts at 72 hpi. Fig-
ure 1 shows the results obtained from 16 out of 24 RCMV
miRNAs compared to the control cellular miRNA miR-16. We
observed the mature form (22 nt) of all of the miRNAs, as
well as the pre-miRNA forms of some of them.
Identification of RCMV miRNA isoforms. Similar to what
has been observed in other studies of viral and cellular
miRNAs, a number of the RCMV miRNAs had considerable
variation at their 3 and 5 ends. As shown in Table 3, the
variation, for the most part, was conserved between the miR-
NAs detected in the infected fibroblasts and those in the rat
salivary gland tissues. However, there were specific examples
where the percentage of the particular miRNA isoform dif-
fered between the two samples. For example, RCMV miR-r6-1
has four major isoforms but only three of these were dominant
in the fibroblasts. One of the isoforms of miR-r6-1 (TCGAC
CTCAAGCCGTTCGGGGACA) was the most highly ex-
pressed isoform detected in salivary gland tissues, but this
isoform was expressed to very low levels in fibroblasts. Simi-
larly, one of the isoforms of RCMV miR-OriLyt-2 was only
detected in the in vivo sample (60% of the sequenced se-
quences for this miRNA) but not in infected fibroblasts. We
also detected the miRNA* (passenger strand) for 13 of the
viral miRNAs, and some of these were detected as major
isoforms, including those for RCMV miR-r6-1, miR-OriLyt-1,
miR-R91-1, and miR-r111.1-1 (Table 3).
FIG. 1. Northern blot analysis of RCMV miRNAs. RFL6 cells were infected at a multiplicity of 1 PFU per cell and subjected to Northern blot
analysis using probes specific for the predicted RCMV miRNA sequences. Lanes M, mock infected; lanes I, infected. The cellular miRNA miR-16
was used as a loading control. The values to the left are molecular sizes in nucleotides.
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TABLE 3. RCMV miRNA sequence isoforms detected in fibroblasts and salivary glands
miR RCMV miR sequence Length(nt)
Fibroblastsa Salivary glandsa
Frequency % Frequency %
miR-r6-1 TCGACCTCAAGCCGTTCGGGAC 22 131 13 9 12
TCCCGTCCACTCCGAGGTCGGT 22 127 13 8 11
TCGACCTCAAGCCGTTCGGGA 21 97 10 6 8
TCGACCTCAAGCCGTTCGGGACA 23 25 3 17 23
miR-OriLyt-1 GACGGGGTCTCGGGCTCCTGA 21 178 31 22 52
GACGGGGTCTCGGGCTCCTGAC 22 110 19 11 26
CCCGGAGCTCGAAACCCGGTTCGb 23 27 5 6 14
miR-OriLyt-2 TGGCTCGCGTCGCCATGGAGAC 22 30 31 ND
GCTCGCGTCGCCATGGAGACA 21 13 13 3 38
TGGCTCGCGTCGCCATGGAGACA 23 0 ND 5 62
miR-R87-1 TCGAAGAACGGGTGCAACTC 20 68,629 41 402 43
TCGAAGAACGGGTGCAACTCT 21 33,774 20 170 18
GAAGAACGGGTGCAACTC 18 14,028 8 99 11
miR-R91-1 GGACTCGGAGTCGTCGGACGCT 22 1,706 26 12 22
GGACTCGGAGTCGTCGGACGCTT 23 972 15 12 22
GACTCGGAGTCGTCGGACGCT 21 467 7 0 ND
CGTTCGACGATCCCCGGTCCTTb 22 191 3 7 13
miR-r111.1-1 CGCACCGGCGTCGAGCACGTAC 22 753 26 28 25
CGCACCGGCGTCGAGCACGTACT 23 427 15 24 21
CGCACCGGCGTCGAGCACGT 20 291 10 18 16
TATGTGCTCGTCACCGGAGGGTb 22 333 12 13 12
miR-r111.1-2 TCGAAACAACGTGGAACGGCGT 22 11,212 37 646 33
TCGAAACAACGTGGAACGGCG 21 4,115 14 161 8
TCGAAACAACGTGGAACGGCGTT 23 3,707 12 488 25
miR-r1-1 GTAAGATGGAATCACCGGAGG 21 5,265 20 27 14
GTAAGATGGAATCACCGGAGGC 22 5,234 20 51 26
GTAAGATGGAATCACCGGAG 20 4,523 17 42 21
GTAAGATGGAATCACCGGAGGCA 23 3,869 15 34 17
GTAAGATGGAATCACCGGAGGCT 23 2,748 10 26 13
miR-r1-2 TTTCTCTCGTGCTCCGTGTCGC 22 610 60 6 100
TTTCTCTCGTGCTCCGTGTCG 21 94 9 0 ND
miR-r43.1-1 TTATCAGCCGGCAAGCACCCAGG 23 1,261 23 9 25
TTATCAGCCGGCAAGCACCCA 21 1,183 21 15 42
TTATCAGCCGGCAAGCACCCAG 22 905 16 12 33
miR-r111.2-1 TACGTGCTCGACGCCGGTGCGG 22 13 28 0 ND
TACGTGCTCGACGCCGGTGCGGA 23 11 23 0 ND
miR-r111.2-2 CTTCGAGTGCGTGTCCGATAGC 22 101 29 5 25
CTTCGAGTGCGTGTCCGATAG 21 95 27 10 50
CTTCGAGTGCGTGTCCGATAGT 22 58 17 5 25
miR-r111.2-3 AATCGGACACCCGCTCGCGAAGG 23 164 15 6 20
AATCGGACACCCGCTCGCGAAG 22 155 14 3 10
ATCGGACACCCGCTCGCGAAGGA 23 114 11 12 39
GGACACCCGCTCGCGAAGGA 20 76 7 4 13
miR-r111.2-4 CCCGAAACTCCGTCGAACGCG 21 418 39 17 57
CCCGAAACTCCGTCGAACGCGC 22 346 32 13 43
miR-r111.2-5 TTCCACGTTGTTTCGAGGCCT 21 1,637 43 45 45
CACGTTGTTTCGAGGCCT 18 739 20 22 22
miR-r111.2-6 TTCGCGGACGATCGAGGAG 19 14,331 25 77 19
TTCGCGGACGATCGAGGAGGCC 22 7,799 14 87 22
TTCGCGGACGATCGAGGAGGC 21 6,162 11 31 8
a ND, not detected.
b miRNA* or passenger strand sequence.
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RCMV miRNA genomic organization. The genomic posi-
tions of the RCMV miRNAs are depicted in Fig. 2. The
RCMV miRNAs are generally distributed across the viral ge-
nome. However, similar to what was observed for other her-
pesviruses, the RCMV miRNAs are often encoded in clusters.
The largest cluster of nine viral miRNAs exists in a 700-bp
region encoding miR-r111.1-1, miR-r111.1-2, miR-r111.1-3,
miR-r111.1-4, miR-r111.2-1, miR-r111.2-2, miR-r111.2-3,
miR-r111.2-4, miR-r111.2-5, and miR-r111.2-6. Of these, only
two pairs (miR-r111.2-2/miR-r111.2-3 and miR-r111.2-4/miR-
r111.2-5) are encoded within the same hairpin loop structure
(Fig. 3), indicating that within this region there are at least
seven individual hairpin loop structures. A cluster of four viral
miRNAs also exists in and near the coding region for the
RCMV gene r1, and two of these (miR-r1-2/miR-r1-3) also
share a hairpin loop. Six of the RCMV-encoded miRNAs
could target RCMV mRNAs because they are directly com-
plementary to RCMV genes, including miR-87-1 (R86), miR-
R91-1 (R90), and miR-r170-1 (r164), as well as miR-r111.2-1,
miR-r111.2-2, and miR-r111.2-3, which target r111.1. One ad-
ditional finding that may have implications for viral persistence
is the fact that we identified two viral miRNAs expressed from
the viral origin of replication, OriLyt.
We compared the miRNA sequences for mouse cytomega-
lovirus (MCMV) and RCMV using the phylogenetic analysis
program Clustal 3.1. There was minimal conservation between
the miRNAs from these two related viruses. However, when
we compared the genomic positions of the miRNAs for
MCMV and RCMV, we observed that most of them had sim-
ilar orientations in the viral genomes (Fig. 4). For example,
both RCMV and MCMV contain clusters of miRNAs at the
extreme 5 end of the genome. MCMV contains six miRNAs
and RCMV contains four miRNAs in this region. RCMV lacks
the MCMV genes (m7 to m22), however; RCMV miR-r6-1 is
positioned near R23, which is a location similar to that of the
cluster of MCMV miRNAs (m21, m22, and m23). Both viral
genomes contain miRNAs in or near OriLyt. While the origi-
nal description of miR-m59-1, -2, and -3 did not suggest this
orientation, further review by our group puts these near the
origin of lytic replication. Interestingly, both viruses also con-
tain clusters of miRNAs on complementary strands of the viral
genomes in a central region near the RCMV and MCMV 112
open reading frames. This region is close to the large stable
intron in MCMV and most likely RCMV, although it has not
yet been specifically mapped for this virus. It appears that, as in
other CMVs, the locations of the RCMV miRNAs share a
genome-wide distribution profile, which is different from the
observed clustering of the alpha- and gammaherpesvirus
miRNAs in latency-associated regions.
Characterization of RCMV miRNA expression. CMV gene
expression in vitro can be divided into three kinetic classes,
immediate early (IE), early, and late, based on the require-
ments of protein synthesis and viral DNA replication. There-
fore, we next sought to determine whether the RCMV
miRNAs found within the 700-bp region near RCMV r111 are
all expressed with the same kinetics or differentially regulated.
We performed a Northern blot analysis of RNA isolated from
RFL6 fibroblasts infected with RCMV for 8, 24, or 48 h, as well
as for 48 h in the presence of foscarnet, which differentiates
early from late viral gene expression (65). Figure 5 demon-
strates that miR-r111.1-1 and miR-r111.2-2 and -3 are ex-
pressed with early kinetics as their expression was not inhibited
by foscarnet treatment. In contrast, miR-r111.1-2 and -3 and
miR-r111.2-1 and -4 were expressed with late kinetics since
their expression was blocked at late times in the presence of
the viral DNA inhibitor.
Since we found that a portion of the RCMV miRNAs were
differentially expressed in fibroblasts and salivary glands, we
hypothesized that, similar to viral gene expression in tissues
(65), viral miRNA expression is also tissue specific. Therefore,
FIG. 2. Genomic organization of RCMV miRNAs. The diagram depicts the regions of the RCMV genome that contain RCMV miRNAs. The
dark gray arrows indicate the positions and directions of the RCMV miRNAs, where right-pointing arrows indicate RCMV miRNAs on the sense
strand and left-pointing arrows indicate miRNAs on the complement strand. Open reading frames that contain or are near viral miRNAs are shown
as light gray block arrows. The RCMV origin of lytic replication is depicted as a dark gray box.
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FIG. 3. Secondary structures of RCMV precursor miRNAs. The predicted stem-loop secondary structures of the RCMV pre-miRNAs from the
Mfold program (68) are depicted with the mature miRNAs shaded in gray. When two miRNAs are transcribed from one stem-loop, the position
of each miRNA is indicated on the 5 or 3 arm of the stem-loop.
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we performed real-time PCR analysis of RCMV miR-R87-1
and miR-r111.1-2 with total RNA prepared from the tissues of
rat heart allograft recipients harvested at 7 and 28 days post-
transplantation. In infected RFL6 fibroblasts, RCMV miR-
R87-1 is expressed at higher levels than miR-r111.1-2 (Fig.
6A), which confirmed the sequencing data described above.
Similarly, RCMV miR-R87-1 was more highly expressed (by at
least 10-fold) than miR-r111.1-2 in tissues from rat heart allo-
graft recipients (Fig. 6B and C). Interestingly, miR-R87-1 was
expressed to high levels in all tissues except native heart tissue
at 7 days posttransplantation, which is the acute phase of
infection. In fact, this viral miRNA was most highly expressed
in the allograft heart tissue at day 7. However, miR-R87-1
expression was dramatically reduced to undetectable levels at
28 days in allograft heart, spleen, liver, kidney, and lung tissues.
The only tissue that expressed miR-R87-1 at 28 days posttrans-
plantation was the salivary gland, albeit at levels that were
7-fold lower than those measured on day 7. RCMV miR-
r111.1-2 is almost exclusively expressed in salivary gland tis-
sues, and the level of expression increased from day 7 to day
28. Importantly, we have previously shown that viral gene ex-
pression profiles are tissue specific and the profiles do not
correlate with viral DNA loads or viral mRNA levels (65).
DISCUSSION
In the present study, we utilized the robust cloning/sequenc-
ing approach (2, 32) to identify the miRNAs expressed by the
Maastricht strain of RCMV in cultured fibroblasts, as well as
salivary glands from infected rats during the persistent phase of
infection. Our study differs from previous studies of CMV
miRNA identification in that we sequenced the RCMV
miRNAs from both acutely infected cells and in vivo persis-
tently infected tissues (7, 15, 16, 21, 47). We identified 24 small
RNAs expressed from the RCMV genome that map to regions
predicted to fold into stem-loop structures. In fact, many of the
RCMV pre-miRNAs were detected by Northern blot analysis.
In addition, we cloned and sequenced the corresponding
FIG. 4. Comparison of genomic positioning of the RCMV and MCMV miRNAs. The diagram depicts the genomic positioning of the miRNAs
expressed by RCMV (lower) and MCMV (upper). The dark gray arrows indicate the positions and directions of the CMV miRNAs, where
right-pointing arrows indicate miRNAs on the sense strands and left-pointing arrows indicate miRNAs on the complement strands. Open reading
frames that contain or are near viral miRNAs are shown as light gray block arrows. The MCMV and RCMV origins of lytic replication are depicted
as black boxes.
FIG. 5. Kinetic analysis of miRNA expression by Northern blotting. Total RNA was harvested with Trizol from RCMV-infected RFL6 rat
fibroblasts at 0, 8, 24, and 48 hpi. Cells were infected at a MOI of 1.0. An additional sample harvested at 48 hpi was treated with Foscavir (foscarnet
sodium; 100 mg/ml) to prevent late gene expression. RNA was subjected to Northern blot analysis using probes specific for the predicted RCMV
miRNA sequences. Lane 1 (0 hpi) was a mock-infected sample. The values to the left are molecular sizes in nucleotides.
VOL. 85, 2011 RCMV-ENCODED miRNAs 385
miRNA* or passenger strand for a number of the miRNAs
discovered in this study. Similar to both HCMV and MCMV
miRNAs, the RCMV miRNAs are found distributed individ-
ually or in clusters across the viral genome, which differs sub-
stantially from their distribution in alpha- and gammaherpes-
viruses (8, 25, 34, 48, 53, 54). Of the 24 identified RCMV
miRNAs, 4 were uniquely detected in the infected fibroblast
sample and 2 were unique to the persistently infected salivary
gland tissue, which is most likely attributed to the natural
variation observed between in vivo and in vitro infection sce-
narios (65). The facts that RCMV miR-r111.1-2 was exclusively
expressed in salivary glands and its expression increased during
persistence whereas miR-R87-1 was downregulated during
persistence suggest that viral miRNA expression is dynamic
and regulated in vivo.
Viral miRNA target discovery and determination of the
relevance of this targeting to virus infection have been intrin-
sically difficult. This problem is compounded for HCMV due to
the species specificity of CMVs and the lack of an appropriate
in vivo animal model for HCMV. However, various in vitro and
bioinformatic studies have identified both cellular and viral
targets of the HCMV miRNAs. For example, miR-UL112 tar-
gets the viral transcription factor IE protein IE72 and UL114
targets the virally encoded uracil DNA glycosylase, which is
important for the transition to late-phase viral DNA replica-
tion (13, 23, 60). A leading hypothesis for the role of miRNAs
is in the establishment of latency due to their ability to down-
regulate IE protein expression especially during the late phase
of lytic replication, when the viral miRNAs accumulate to high
levels. Subsequently, once latency is established, viral miRNA
targeting of the IE genes may help to maintain latency by
inhibiting initiation of the lytic cascade. In fact, a common
feature of most herpesvirus miRNAs is the targeting of expres-
sion of viral transactivators, including the herpes simplex virus
type 1 (HSV-1) miR-LAT target ICP0, the Epstein-Barr virus
(EBV) miR-BHRF-1 and miR-BART15 targets BZLF1 and
BRLF1, respectively, and the Kaposi’s sarcoma herpesvirus
(KSHV) miR-K10-6-3p targets Rta and Zta (43). In addition,
HCMV miR-US25-1 and miR-US25-2 miRNAs may contrib-
ute to the establishment of latency since they were recently
shown to reduce viral replication and DNA synthesis of not
only HCMV but other DNA viruses as well (HSV-1 and ade-
novirus) (60). Thus, it was hypothesized that miR-US25-1 and
miR-US25-2 target cellular genes essential for virus growth.
Recently, Grey et al. demonstrated that HCMV miR-US25-1
FIG. 6. RCMV miRNA expression in tissues from RCMV-infected
allograft recipients. The level of RCMV miRNA expression was de-
termined by RT-PCR analysis of total RNA samples. Shown are viral
miRNA copy numbers determined using dilutions of an oligonucleo-
tide standard with the specific miRNA sequences of miR-R87-1 and
miR-r111.1-2. (A) Quantification of RCMV miRNA miR-R87-1 and
miR-r111.1-2 expression in RCMV-infected fibroblasts at 0, 6, 24,
and 72 hpi. Uninfected cells (time zero) were included as a negative
control. Both viral miRNAs accumulate with increasing time. (B) RT-
PCR results for RCMV miR-R87-1 from tissues harvested from
RCMV-infected heart allograft recipients (n  3) at 7 and 28 days
posttransplantation. RCMV miR-R87-1 was most highly expressed in
the allograft heart, spleen, and lung tissues at 7 days posttransplanta-
tion. (C) RT-PCR results for RCMV miR-r111.1-2 from tissues har-
vested from RCMV-infected heart allograft recipients (n  3). miR-
r111.1-2 was most highly expressed in salivary glands at 7 and 28 days
posttransplantation. ND, not detected.
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targets multiple cellular genes related to cell cycle control,
specifically, the gene for cyclin E2 (24). Multiple EBV and
KSHV miRNAs also target cellular pathways involved in apop-
tosis and cell cycle regulation (11, 33, 67). HCMV, KSHV, and
EBV encode a miRNA that targets the NK cell-activating
ligand MICB, and its downregulation leads to decreased viral
infected cell killing (59). Thus, it appears that expression of
viral miRNAs provides herpesviruses a nonimmunogenic strat-
egy to stably alter the cellular environment during persistence.
Importantly, the types of genes and pathways targeted by
viral miRNAs are most likely cell type specific and this fact
must be taken into consideration when identifying targets of
the viral miRNAs. To date, most of the tissues examined for
miRNA expression show that cellular miRNA expression is not
only cell type specific but also dependent upon the differenti-
ation of that cell type (3, 34). Examination of miRNA expres-
sion in 17 hematopoietic cell lines was compared to that in
purified human B cells, T cells, monocytes, and granulocytes
and was found to have considerable differences based upon cell
type and differentiation status (50). Similarly, differential
miRNA expression is documented for viruses. We identified
two RCMV miRNAs that were expressed in salivary glands but
not in acutely infected fibroblasts and four that were not ex-
pressed during persistence in salivary glands (Table 2). In
addition, the expression patterns of miR-R87-1 and miR-
r111.1-2 differ in their tissue expression and timing following
infection (Fig. 6). EBV BART and BHFR miRNAs are con-
trolled by different virus latency programs, and they are differ-
entially expressed in lymphoid and epithelial cells (9, 49).
EBV-associated primary tumors have high levels of miR-
BART (66). Conversely, in AIDS diffuse large B-cell lympho-
mas, only BHRF miRNAs were detected but BHRF2 miRNAs
were not detected in nasopharyngeal carcinoma tumors (12).
An additional level of control of viral miRNA expression and
targeting specificity exists due to the heterogeneous processing
of the 5 and 3 ends of the miRNA. We and others have
observed that pre-miRNA processing can produce distinct iso-
forms of miRNA-miRNA* duplexes with 5 and 3 heteroge-
neity (Table 3 and reference 10). The mechanisms of how
miRNA isoforms are derived and the extent of their differen-
tial function are still unknown. However, recent studies pro-
vide evidence to suggest that miRNA length isoforms are rel-
atively common and that a single pre-miRNA hairpin can be
differentially processed to give rise to several functional
miRNAs with various biological properties (1, 17–19). Inter-
estingly, the differences in biological function may be attrib-
uted to the fact that the length isoforms can utilize unique
Argonaute-RISC protein complexes (17). Alternative process-
ing at the 5 end would switch the seed sequence of the
miRNA, alter target recognition, and act to broaden the reg-
ulatory impact of the miRNA (19). Interestingly, we also ob-
served differential isoform usage between the in vitro fibroblast
samples and the in vivo salivary gland samples. A specific
isoform of miR-OriLyt-2 was only detected in the salivary
gland sample and not in the fibroblast sample. This finding
highlights the importance of determining the role of miRNA
heterogeneity in vivo. Thus, herpesvirus miRNAs possibly play
particular roles during the infection of differentiated cell types,
making it critical to understand cell and tissue type-specific
miRNA expression in order to elucidate miRNA function.
An important characteristic of the miRNAs encoded by
MCMV and RCMV is the finding that there are at least two
miRNAs for each virus encoded in or directly adjacent to the
origin of lytic replication. The function of these miRNAs is still
unknown. However, they may play an important role in viral
DNA replication. It has been shown that a small RNA stem-
loop structure encoded by EBV mediates the recruitment of
the origin recognition complex to OriP by binding ORC1 and
the RGG motifs of EBNA-1 (44). This promotes the assembly
of the replication complex at OriP but occurs in the absence of
RNA-DNA binding. Thus, another plausible role for viral
miRNAs encoded in OriLyt might be in DNA replication by
directly binding DNA at the origin. It is possible that the viral
miRNA might act as the RNA primer, normally synthesized by
the host primase, that base pairs with the DNA at the origin of
replication to initiate DNA synthesis. This would be especially
important for the initiation of viral DNA synthesis in nondi-
viding cells during reactivation from latency. Further experi-
mentation to characterize the role of these miRNAs in viral
replication is warranted and may lead to the development of
novel therapeutics that target and exploit this interesting rela-
tionship. The aim of this study was to identify the small RNAs
encoded in the RCMV genome and determine in vivo viral
miRNA expression in RCMV-infected rats. This knowledge
will enable us to characterize the in vivo roles and relevance of
CMV-encoded miRNAs during acute and persistent infec-
tions, latency/reactivation, and pathogenesis.
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